Valuation: Prostatype Genomics AB

Market Cap 9.56M 986K 866K 805K 739K 1.39M 94.91M 1.41M 3.73M 46.66M 3.7M 3.62M 161M P/E 2024
-0.38x
P/E 2025 -0.23x
Enterprise Value 5.79M 597K 524K 488K 448K 841K 57.5M 854K 2.26M 28.27M 2.24M 2.19M 97.74M EV / Sales 2024
33.9x
EV / Sales 2025 23.6x
Free-Float
27.07%
Yield 2024 *
-
Yield 2025 -
1 day+6.60%
1 week-11.02%
Current month-62.44%
1 month-65.86%
3 months-79.56%
6 months-89.84%
Current year-46.17%
1 week 0.13
Extreme 0.13
0.2
1 month 0.13
Extreme 0.13
0.75
Current year 0.13
Extreme 0.13
2.28
1 year 0.13
Extreme 0.13
2.28
3 years 0.13
Extreme 0.13
404
5 years 0.13
Extreme 0.13
17,940
10 years 0.13
Extreme 0.13
18,400
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Director of Finance/CFO - 2023-10-30
General Counsel - 2023-02-28
Director TitleAgeSince
Chairman - 2016-12-31
Director/Board Member - 2017-12-31
Director/Board Member 74 2018-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+6.60%-11.02%-84.84%-99.96% 986K
-1.02%-3.46%+88.62%+456.36% 37.52B
+1.98%+4.73%+12.01%+33.86% 24.34B
+2.02%-3.02%-24.40%-39.44% 7.33B
+0.97%-1.00%+7.25%+82.27% 4.84B
+4.27%+4.26%+14.34%+47.64% 3.05B
-2.46%-4.93%+120.83%-16.53% 1.81B
-2.07%-1.52%-14.29%-63.84% 1.78B
-6.75%-6.90%-25.97%+695.42% 1.75B
+5.58%-1.99%+12.29%+2.91% 1.74B
Average +0.91%-2.60%+10.58%+109.87% 8.42B
Weighted average by Cap. +0.38%-0.69%+43.79%+229.11%

Financials

2024 2025
Net sales 1.92M 198K 174K 162K 148K 278K 19.04M 283K 749K 9.36M 742K 726K 32.37M 594K 61.24K 53.79K 50.02K 45.9K 86.25K 5.9M 87.58K 232K 2.9M 230K 225K 10.03M
Net income -41.05M -4.23M -3.72M -3.46M -3.17M -5.96M -408M -6.05M -16.04M -200M -15.89M -15.55M -693M -44.5M -4.59M -4.03M -3.75M -3.44M -6.46M -442M -6.56M -17.39M -217M -17.22M -16.85M -751M
Net Debt -9.35M -964K -847K -788K -723K -1.36M -92.86M -1.38M -3.65M -45.65M -3.62M -3.54M -158M -3.77M -388K -341K -317K -291K -547K -37.41M -556K -1.47M -18.39M -1.46M -1.43M -63.59M
Logo Prostatype Genomics AB
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Employees
7
Date Price Change Volume
26-07-24 SEK 0.1615 +6.60% 257,847
26-07-23 SEK 0.1515 +11.40% 554,580
26-07-22 SEK 0.1360 -12.26% 1,722,447
26-07-21 SEK 0.1550 -13.89% 674,536
26-07-20 SEK 0.1800 -0.83% 489,982
  1. Stock Market
  2. Stocks
  3. PROGEN Stock